CymaBay Therapeutics shares are trading higher after the company announced the FDA revised the originally granted Breakthrough Therapy Designation for seladelpar to now reflect the treatment of primary biliary cholangitis, including pruritus in adults without cirrhosis or with compensated cirrhosis.
Portfolio Pulse from Benzinga Newsdesk
CymaBay Therapeutics announced that the FDA has revised the Breakthrough Therapy Designation for seladelpar to include the treatment of primary biliary cholangitis, including pruritus in adults without cirrhosis or with compensated cirrhosis. This news has led to a rise in the company's stock.
October 23, 2023 | 6:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA's revision of the Breakthrough Therapy Designation for CymaBay's seladelpar has led to a rise in the company's stock.
The FDA's revision of the Breakthrough Therapy Designation for seladelpar expands its use, potentially leading to increased sales and revenue for CymaBay. This positive news has led to a rise in the company's stock, indicating investor confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100